The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Parkinson’s Disease Therapeutics Pipeline Program, 2024Development of Selective Ion Channel Inhibitors as a Disease-modifying Therapy for Parkinson’s Disease
Study Rationale: Our aim is to develop an oral medication that will protect the dopamine neurons whose loss is thought to be the cause Parkinson’s disease (PD). Evidence suggests that excessive levels...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2024Examining the Effects of MTX325 on Mitochondrial Quality Control and the Prevention of Parkinson’s Disease Progression
Study Rationale: Mitochondria generate the energy needed for cells to work properly, and impaired mitochondrial function has been linked to the loss of dopamine neurons in multiple forms of Parkinson...
-
[RFA] Use of PD Biosamples - Spring 2020, 2024Neurotoxic Inflammatory Metabolites as Biomarkers of Disease Progression in Parkinson’s Disease
Study Rationale: Individuals with Parkinson’s disease (PD) have inflammation in the brain, cerebrospinal fluid and the blood. We think that inflammation drives the worsening of PD because it increases...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2024A Clinical Trial to Investigate the Safety of Repeated Subcutaneous Injections of HER-096, a Novel Candidate for Disease-modifying Therapy in Parkinson’s Disease
Study Rationale: sHER-096 is a novel compound that mimics CDNF, a human neurotrophic factor that has shown neuroprotective and neurorestorative properties in an animal model of Parkinson’s disease (PD...
-
Research Grant, 2024Chronos-PD Pilot: Analyzing Plasma from Donors Who Develop Parkinson’s Disease Later in Life
Study Rationale: Our current molecular understanding of Parkinson’s disease (PD) is based on the clinical phase of the disease. However, because PD is a progressive disease, by the time the disorder...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2024Therapeutic Development of Novel STING Inhibitors to Treat Parkinson's Disease Neuroinflammation
Study Rationale: Brain inflammation plays an important role in the pathology and progression of Parkinson’s disease (PD). One of the key proteins involved in this inflammatory process is STING...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.